

REMARKS

Amendment of Specification

The specification has been amended to claim priority to U.S. Patent Application No. 09/491,500 filed January 26, 2000, entitled "Method for Using Potassium Channel Agonists for Delivering a Medicant to an Abnormal brain Region and/or Malignant Tumor."

Amendment of Claims

After entry of the amendment, claim 1 and claims 110-203 remain pending. Claims 2-109 have been cancelled. Claims 1-167 are directed to a method of delivering a medicant to an abnormal brain region involving administering a calcium-activated potassium channel agonist and a medicant. Claims 168-183 are directed to a pharmaceutical composition including a combination of a calcium-activated potassium channel agonist and a therapeutic cytotoxic agent. Claim 184-199 are directed to a pharmaceutical combination comprising a calcium-activated potassium channel agonist and a drug. Claims 200-203 are directed to a kit for delivering a medicant to an abnormal brain region including a calcium-activated potassium channel agonist.

Applicants also submit an Information Disclosure Statement and 1449 Form with this continuation application.

Respectfully submitted,



Sherry M. Knowles, Esq.
Reg. No. 33,052

King & Spalding
191 Peachtree St.
Atlanta, Georgia 30303
404-572-3541
404-572-5145 (fax)